AJOVY DIN 02497859
Status: Marketed
Holder: TEVA CANADA LIMITED
Available to quote
Health Canada record
| Active ingredient(s) | FREMANEZUMAB 225 MG |
|---|
| Dosage form | Solution |
|---|
| Route | Subcutaneous |
|---|
| Schedule | PRESCRIPTION; SCHEDULE D |
|---|
| Class | Human |
|---|
| ATC | N02CD03 FREMANEZUMAB |
|---|
| Original market date | 04-Aug-2020 |
|---|
| Current status date | 04-Aug-2020 |
|---|
| Source | Health Canada DPD |
|---|
Establishment licence of the holder
Teva Canada Limited — licence 101810, currently licensed, last inspection rating C (2025-03-04).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing FREMANEZUMAB
| DIN | Product | Company | Form | Strength | Status |
|---|
| 02509474 | AJOVY | TEVA CANADA LIMITED | Solution | FREMANEZUMAB 225 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|
| 23441 | 2020-04-09 | New Drug Submission (NDS) | |
Request a quote for AJOVY
How to read a Canadian DIN record